Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease

Meier, Claus; Freiburghaus, K.; Bovet, Cédric; Schniering, Janine; Allanore, Yannick; Distler, Oliver; Nakas, Christos T.; Maurer, Britta

doi:10.1038/s41598-020-78951-6

Cited by 14 publications

(14 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Herein, were investigated how levels of serum metabolites correlated with different stages of SSc and SSc-ILD [15]. Serum samples of patients with SSc without ILD, stable and progressive SSc-ILD as well as of healthy controls (HC) were analyzed using liquid targeted tandem mass spectrometry.…”

Section: Resultsmentioning

confidence: 99%

Novel biomarkers in systemic sclerosis

Agachi¹,

Groppa²,

Rotaru³

et al. 2022

MJHS

View full text Add to dashboard Cite

Introduction. Due to the heterogeneous nature of systemic sclerosis, it is difficult to predict disease progression and complications. Despite the discovery of novel autoantibodies associated with systemic sclerosis (SSc), there is an unmet need for biomarkers for diagnosis, disease progression, and response to treatment. Materials and methods. An analytical, qualitative study was performed with a narrative review of literature in the form of a synthesis article. Relevant primary sources published in 2020-2022 were identified and selected, using data extraction and analysis. Results. Anti-citrullinated protein/peptide antibody could be useful in identifying patients with a more prominent joint disease. Of most interest, the anti-carbamylated protein antibodies (anti-CarP) could be a relevant biomarker related to fibrotic skin and lung disease. Positive anti-RNA (Ribonucleic acid) polymerase III antibody and antinuclear antibodies (ANA) negativity were significantly associated with GAVE (gastral antral vascular ectasia). Autoantibodies against telomeres may help identify systemic sclerosis with lung disease. Osteopontin links myeloid activation and disease progression in systemic sclerosis. CTRP (C1q tumor necrosis factor-related proteins) 9 protein levels may be biomarker of lung disease severity. CD (cluster differentiation) 21-low B cells are linked to vascular damage. L-tyrosine, L-tryptophan, and 1-methyl-adenosine distinguished healthy controls from SSc patients. L-leucine, L-isoleucine, xanthosine, and adenosine monophosphate differentiated between progressing and stable SSc-ILD. CECs (circulating endothelial cells) are a direct indicator of systemic vascular damage. Levels of the protein, galectin-3, are associated with heart involvement in people with systemic sclerosis. Low levels of the galectin-10 protein (Gal-10) in scleroderma patients associate with inflammation and vascular changes in the lungs, leading to pulmonary arterial hypertension (PAH). High levels of the CD146 protein may be a potential biomarker in identifying people with systemic sclerosis. Blood levels of the protein endocan increased in scleroderma patients who are at risk for pulmonary arterial hypertension. FLCs (free light chain) could be employed as useful potential biomarker of early diagnosis and to follow disease activity. Conclusions. Novel discovered biomarkers could predict disease development, activity, and severity of diverse organ involvement, predict risk of complications of systemic sclerosis.

show abstract

Section: Resultsmentioning

confidence: 99%

Novel biomarkers in systemic sclerosis

Agachi¹,

Groppa²,

Rotaru³

et al. 2022

MJHS

View full text Add to dashboard Cite

show abstract

“…Zhao et al compared IPF patients with controls and found that IPF patients showed metabolic disorders in biochemical indexes such as glycolysis, mitochondrial β oxidation and tricarboxylic acid cycle, fatty acid β oxidation, bile acid level, heme level, and glutamate/aspartic acid ratio 24 . These findings have led researchers to boldly hypothesize that a specific metabolic pathway is involved in cell remodeling in IPF patients, and successfully transformed myofibroblasts into fibroblasts and activated extracellular matrix degradation, which provides a new perspective for scientific research and clinical treatment 4,6,21,24,57–69 . These pathways involve intracellular transport of metabolites mediated by signal transition through down‐regulated sphingolipids and up‐regulated arginine.…”

Section: Exploring the Pathogenesis Of Ipf Through Metabolomicsmentioning

confidence: 99%

“…24 These findings have led researchers to boldly hypothesize that a specific metabolic pathway is involved in cell remodeling in IPF patients, and successfully transformed myofibroblasts into fibroblasts and activated extracellular matrix degradation, which provides a new perspective for scientific research and clinical treatment. 4,6,21,24,[57][58][59][60][61][62][63][64][65][66][67][68][69] These pathways involve intracellular transport of metabolites mediated by signal transition through downregulated sphingolipids and up-regulated arginine. Further research is needed to determine the role of these pathways in IPF pathogenesis and potential treatment targets.…”

Section: Exploring the Pathogenesis Of Ipf Through Metabolomicsmentioning

confidence: 99%

The application of metabolomics toward idiopathic pulmonary fibrosis and potential metabolomic value of diverse samples in interstitial lung diseases

Liu

Cheng

Xue

et al. 2023

Precision Medical Sciences

View full text Add to dashboard Cite

Interstitial lung diseases (ILDs), also known as diffuse lung diseases, pose a significant challenge to the respiratory health of individuals worldwide. Among these conditions, idiopathic pulmonary fibrosis (IPF) is one of the most prevalent, contributing substantially to morbidity and mortality. However, IPF is characterized by high heterogeneity, presenting a substantial obstacle to clinical program development and scientific research due to significant variations in disease progression, treatment response, and prognosis. Recent advances in metabolomics have enabled the identification of specific biochemical pathways and disease biomarkers, offering a beacon of hope for patients afflicted with various diseases. Remarkably, metabolomics has made significant strides in ILDs, particularly in IPF. Metabonomics, a branch of life science, provides an in‐depth analysis of metabolic pathways and the specific biological molecular composition of omics, obtained primarily from biological samples such as serum, plasma, pleural effusion, bronchoalveolar lavage fluid, lung surgical biopsy samples, urine, feces, sputum, and cerebrospinal fluid. In this review, we aim to provide a comprehensive overview of the application of metabolomics in ILDs, with a particular focus on IPF. By summarizing the current state of research in this field, we hope to shed light on the latest advances, challenges, and opportunities that metabolomics can provide in managing ILDs.

show abstract

“…During the last few decades, the pathogenesis of SSs has been focused on microvasculopathy and endothelial dysfunction, principally manifested by digital ulcers and Raynaud’s phenomenon, which could determine progressive tissue fibrosis and, finally, organ tissue damages [ 3 ]. Recently, different studies have demonstrated, in SSc, an association between endothelial dysfunction, cardiovascular disease (CVD), and atherosclerosis [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

Association of Systemic Sclerosis and Periodontitis with Vitamin D Levels

et al. 2021

View full text Add to dashboard Cite

The aim of the present study was to analyze the association among systemic sclerosis (SSc), periodontitis (PT); we also evaluated the impact of PT and SSc on vitamin D levels. Moreover, we tested the association with potential confounders. A total of 38 patients with SSc, 40 subjects with PT, 41 subjects with both PT and SSc, and 41 healthy controls were included in the study. The median vitamin D levels in PT subject were 19.1 (17.6–26.8) ng/mL, while SSc + PT group had vitamin d levels of 15.9 (14.7–16.9) ng/mL, significantly lower with respect to SSc patients (21.1 (15.4–22.9) ng/mL) and to healthy subjects (30.5 (28.8–32.3) ng/mL) (p < 0.001). In all subjects, vitamin D was negatively associated with c-reactive protein (CRP) (p < 0.001) and with probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP), and plaque score (PI) (p < 0.001 for all parameters) and positively related to the number of teeth (p < 0.001). Moreover, univariate regression analysis demonstrated an association among high low-density lipoproteins (LDL) cholesterol (p = 0.021), CRP (p = 0.014), and PT (p < 0.001) and reduced levels of vitamin D. The multivariate regression analysis showed that PT (p = 0.011) and CRP (p = 0.031) were both predictors of vitamin D levels. Subjects with PT and SSc plus PT had significant lower vitamin D values with respect to SSc and to healthy subjects. In addition, PT seems negatively associated with levels of vitamin D in all analyzed patients.

show abstract

Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease

Cited by 14 publications

References 54 publications

Novel biomarkers in systemic sclerosis

Novel biomarkers in systemic sclerosis

The application of metabolomics toward idiopathic pulmonary fibrosis and potential metabolomic value of diverse samples in interstitial lung diseases

Association of Systemic Sclerosis and Periodontitis with Vitamin D Levels

Contact Info

Product

Resources

About